
Shares of drug developer Vir Biotechnology VIR.O rise 65.2% at $12.28 premarket
Co posts Q4 revenue of $64.1 mln, beating analyst est. of $23.1 mln; posts Q4 loss per share of 31 cents, compared with the consensus of loss of 49 cents - data compiled by LSEG
Co highlights its agreement with Norgine and lower R&D expenses due to restructuring initiatives
Co also plans to develop and commercialize its prostate cancer experimental drug with Japan's Astellas 4503.T
As of last close, VIR stock up 23.2% YTD, following a 17.8% decline in 2025